Currently out of the existing stock ratings of Jonathan Wolleben, 151 are a BUY (99.34%), 1 are a HOLD (0.66%).

Jonathan Wolleben

Work Performance Price Targets & Ratings Chart

Analyst Jonathan Wolleben, currently employed at JMP, carries an average stock price target met ratio of 20.93% that have a potential upside of 64.79% achieved within 150 days.

Jonathan Wolleben’s has documented 299 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BCRX, BioCryst Pharmaceuticals at 31-Jan-2025.

Wall Street Analyst Jonathan Wolleben

Analyst best performing recommendations are on DBVT (DBV TECHNOLOGIES).
The best stock recommendation documented was for DBVT (DBV TECHNOLOGIES) at 9/24/2024. The price target of $5 was fulfilled within 111 days with a profit of $4.27 (584.93%) receiving and performance score of 52.7.

Average potential price target upside

of $101.77 (73.05%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $21.86 (92.42%) on CRNX (CRINETICS PHARMACEUTICALS).
of $12.36 (144.04%) on PHVS (PHARVARIS BV).

ALT Altimmune CLSD Clearside Biomedical CRNX Crinetics Pharmaceuticals DBVT DBV Technologies LRMR Larimar Therapeutics OCUL Ocular Therapeutix PRQR ProQR Therapeutics BV BCRX BioCryst Pharmaceuticals RLYB Rallybio Corp PHVS Pharvaris BV MDGL Madrigal Pharmaceuticals AURA Aura Biosciences PTGX Protagonist Therapeutics ALLK Allakos MIRM Mirum Pharmaceuticals SPRB Spruce Biosciences

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Patrick Trucchio (HC WAINWRIGHT)